Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1416399 | 1.00 | TAAR1 (0.41) | TAAR1RIPK1ADRA2AADRA2CCYP2D6 | |
| SCHEMBL13852044 | 1.00 | TAAR1 (0.41) | TAAR1RIPK1ADRA2AADRA2CCYP2D6 | |
| SCHEMBL19706344 | 0.86 | PTGS2 (0.48) | ALDH1A1 | |
| SCHEMBL24682880 | 0.82 | HTR2A (0.42) | TAAR1ADRA2CLMNASIGMAR1 | |
| SCHEMBL13563587 | 0.82 | RIPK1 (0.43) | TAAR1RIPK1ADRA2AADRA2CCYP2D6 | |
| SCHEMBL12346316 | 0.81 | LTA4H (0.47) | ALDH1A1 | |
| SCHEMBL12354676 | 0.81 | LTA4H (0.47) | ALDH1A1 | |
| SCHEMBL16785292 | 0.79 | PTPN5 (0.41) | CYP2D6LMNAHIF1AKDM4EALDH1A1 | |
| SCHEMBL13852045 | 0.77 | IDO1 (0.39) | KDM4EALDH1A1 | |
| SCHEMBL12602992 | 0.77 | CHRNA7 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663502-B2 | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2017-05-30 | — | — | US | claimed |
| WO-2024042316-A1 | PYRIDO-PYRAZOLES AS INHIBITORS OF DDR'S FOR THE TREATMENT OF FIBROTIC DISORDERS AND CANCER | REDX PHARMA PLC. (GB) | 2024-02-29 | — | — | WO | disclosed |
| EP-3816158-B1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS IDH1 INHIBITORS | KPC PHARMACEUTICALS INC (CN) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023079291-A1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | REDX PHARMA PLC (GB) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023021278-A1 | PHENYL- AND PYRIDOPYRAZOLE DERIVATIVES AS INHIBITORS OF DDR1 | REDX PHARMA PLC (GB) | 2023-02-23 | — | — | WO | disclosed |
| EP-3816158-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS IDH1 INHIBITORS | KPC Pharmaceuticals, Inc. (CN) | 2021-05-05 | — | — | EP | disclosed |
| EP-3782994-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | Loxo Oncology, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3390395-B1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY INC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10662208-B2 | Hydrosilylation process using a germylene-based organic catalyst | ELKEM SILICONES FRANCE SAS (FR) | 2020-05-26 | — | — | US | disclosed |
| EP-3233858-B1 | ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2007118900-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2006040178-A9 | ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2007-04-19 | — | — | WO | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070015731-A1 | 5,6-Di-substituted oxadiazolopyrazines and thiadiazolopyrazines as CXC-chemokine receptor ligands | MERCK SHARP & DOHME CORP. | 2007-01-18 | — | — | US | disclosed |
| US-20070010672-A1 | Fluorescent diketopyrrolopyrroles | CLAP CO., LTD. (KR) | 2007-01-11 | — | — | US | disclosed |
| US-20070010672-A1 | Fluorescent diketopyrrolopyrroles | CLAP CO., LTD. (KR) | 2007-01-11 | — | — | US | disclosed |
| WO-2006040182-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | disclosed |
| EP-1053990-A2 | A method of producing an aromatic ketone and an aromatic ketone composition containing it | TORAY INDUSTRIES, INC. (JP) | 2000-11-22 | — | — | EP | disclosed |
| EP-0695295-A1 | 3-(HETERO)ARYL CARBOXYLIC ACID DERIVATIVES, METHODS OF PREPARING THEM AND INTERMEDIATES USED IN THEIR PREPARATION | BASF AKTIENGESELLSCHAFT (DE) | 1996-02-07 | — | — | EP | disclosed |
| US-5405867-A | Milbemycin derivatives with insecticidal and anthelmintic properties; for plants and animals | SANKYO COMPANY, LIMITED (JP) | 1995-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, ACKR3, CXCR1 | TAAR1 518/4885RIPK1 1964/4885ADRA2A 1532/4885 |
| US-20070015731-A1 | 5,6-Di-substituted oxadiazolopyrazines and thiadiazolopyrazines as CXC-chemokine receptor ligands | CXCR5, CCR5, CXCR1 | TAAR1 408/4885RIPK1 2326/4885ADRA2A 639/4885 |
| US-20070010672-A1 | Fluorescent diketopyrrolopyrroles | TYR, QDPR, MC1R | TAAR1 1135/4885RIPK1 2321/4885ADRA2A 1866/4885 |
| US-10662208-B2 | Hydrosilylation process using a germylene-based organic catalyst | GMNN, HACL2, HVCN1 | TAAR1 3549/4885RIPK1 2152/4885ADRA2A 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.